1 Stock You Need to Sell Before the Next Bull Market
Despite the long-lived loyalty of Novavax's (NASDAQ: NVAX) boisterous base of retail investors called the "Nova-stans," the company's seemingly endless struggles appear poised to burden it to the point of collapse. Management is openly musing about the prospect of going into bankruptcy, and its shares are down by over 79% in the last six months alone.
While it's faintly possible that the biotech will survive, investors shouldn't stick around to find out, and it's probably also time to do some soul-searching about the merits of deciding to become one of its shareholders in the first place. Here's why.
At the moment, Novavax has a gnarly complex of problems that it has no way of solving.
Source Fool.com
